Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
about
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionImportance of relating efficacy measures to unbound drug concentrations for anti-infective agentsMathematical model of plasmid-mediated resistance to ceftiofur in commensal enteric Escherichia coli of cattleDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingMutant prevention concentration, pharmacokinetic-pharmacodynamic integration, and modeling of enrofloxacin data established in diseased buffalo calves.A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against gram-negative bacteria collected from Shenyang, China.Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Prospective monitoring of cefepime in intensive care unit adult patientsVancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensDiet-induced alterations of host cholesterol metabolism are likely to affect the gut microbiota composition in hamsters.Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosaPharmacokinetic study on pradofloxacin in the dog - comparison of serum analysis, ultrafiltration and tissue sampling after oral administrationProspective determination of plasma imipenem concentrations in critically ill children.In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?How fitness reduced, antimicrobial resistant bacteria survive and spread: a multiple pig-multiple bacterial strain model.Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia.Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulationPharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjectsIn vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves.Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patientsPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosisOptimizing the initial amikacin dosage in adults.A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004
P2860
Q26753831-D8B1420D-809F-4E1D-8AAA-9EE423692677Q26827380-D39B8EFA-B021-4504-AD1A-737AC330B9FEQ28483752-0D209906-958B-4120-AE68-4AE18F627A7CQ28550711-97E76E11-9D8B-455E-9ADE-193B36F30E83Q30911044-F35EBB19-C6DF-411A-9287-F2734844A734Q31059319-176CC5BE-F985-4A0A-A038-38BC9099035EQ33508985-F8050A6C-B9CA-40BB-95EB-576FEDFED9C7Q33603799-49AE3070-D8AF-4415-BBE3-C6138F9DEB64Q33876563-CC94C2B3-7424-4EC3-982B-596BC4DE0046Q33919165-D639C116-C8A5-4FB9-9D2D-66977DE7F017Q34026240-B5C9C7A7-4338-4401-BEAD-F5CB1BA8A9A9Q34058137-1DDA8740-CB69-4629-B997-A13EBD47F0D8Q34381321-C0B0D560-CDDB-4F19-A1EC-6B408463D587Q34466299-97C57EC1-16DF-4EAE-B830-835B18E129EEQ34509793-E4052384-7617-4425-A9E0-018AE742BDEEQ34587450-7914504B-D558-4CD1-9DFA-141CD657B8B8Q34721638-0E58FE32-F060-4500-8228-EA7CF1E33B80Q34788573-ABC35E54-2C52-4B5F-8167-7095E4B57919Q35005092-F7A4FD8F-A06E-41D7-92CA-C75F9AD002E5Q35105913-B8BA92D4-39E0-4243-8D3A-AD546768583FQ35124710-001E984E-B41F-47E4-8D78-82F4EF0F842EQ35127800-DB05B669-54EF-4076-A5AD-35B21AB1EA8AQ35143793-D286B979-32BD-4731-89B6-3B97B7EAC166Q35203684-DAC0307F-0AD2-4282-B383-EDA5EDBC06C5Q35270646-18C8E108-627D-485E-ABAF-BCE33A596CC2Q35408518-88E0C2FD-DA7C-4CDB-90CF-A6CFBC97B89BQ35598398-A8666F83-A514-41B7-9A83-3F2649762B57Q35644095-7A4DE5F5-63AD-421F-9A98-D41133CF2F51Q35746176-2F4F851B-B2D7-445C-AB1B-7490BECE533FQ35857801-AF608CF8-CB19-46A4-BDA7-E291BFB0BC82Q35878860-4E2F2E0D-7233-4605-BFEF-8D4F95D6F5BCQ35879111-BC7A2440-A3DD-4F48-9E32-690E7B808252Q35884208-E5683A87-7046-45EB-9458-479F806B29A6Q35941209-DFC5049A-3308-40A3-9FF5-DF6411832B6BQ36018719-1684D204-2F5E-4D24-9256-1E6E4A772BC2Q36072500-DA4D4E59-D8D4-4EAF-AB28-24CC3C5E88DAQ36083619-EAD28251-CE6D-47DF-A148-0B0073BD8077Q36086373-20C400C4-7D35-42AA-8C8B-A29C779F9C86Q36158283-86F34D34-8B56-45EF-9238-4E917DE59B1EQ36259710-186A6B94-B16C-4B50-B2B0-103E66780BB7
P2860
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Standardization of pharmacokin ...... ti-infective drugs: an update.
@ast
Standardization of pharmacokin ...... ti-infective drugs: an update.
@en
type
label
Standardization of pharmacokin ...... ti-infective drugs: an update.
@ast
Standardization of pharmacokin ...... ti-infective drugs: an update.
@en
prefLabel
Standardization of pharmacokin ...... ti-infective drugs: an update.
@ast
Standardization of pharmacokin ...... ti-infective drugs: an update.
@en
P2093
P2860
P356
P1476
Standardization of pharmacokin ...... ti-infective drugs: an update.
@en
P2093
George L Drusano
Hartmut Derendorf
Johan W Mouton
Michael N Dudley
P2860
P304
P356
10.1093/JAC/DKI079
P407
P577
2005-03-16T00:00:00Z